Last year, five scientific journals published prominent articles trumpeting cannabinoids (compounds in marijuana) as potential anti-cancer agents.
Clinical trial data published in January 2003 issue of the Journal of the American Society of Clinical Investigation that found cannabinoids significantly inhibit skin tumor growth in mice. Investigators of the study concluded, “The present data indicate that local cannabinoids administration may constitute an alternative therapeutic approach for the treatment of non-melanoma skin cancer.”
Clinical trial data published in the March 2003 issue of The FASEB Journal that found that the “local administration of a non-psychoactive cannabinoid inhibits angiogenesis (tissue growth) of malignant gliomas (brain tumors).”
A clinical review in the October 2003 issue of the prestigious journal Nature Reviews Cancer that concluded that cannabinoids’ “favorable drug safety profile” and proven ability to inhibit tumor growth make them desirable agents in the treatment of cancer. According to the review’s author, tumors inhibited by cannabinoids include: lung carcinoma, glioma, thyroid epithelioma, lymphoma/leukemia, skin carcinoma, uterus carcinoma, breast carcinoma, prostate carcinoma, and neuroblastoma (a malignant tumor originating in the autonomic nervous system or the adrenal medulla and occurring chiefly in infants and young children).
Clinical trial data published in the November 2003 issue of the Journal of Pharmacology and Experimental Therapeutics that found the administration of the cannabinoid cannabidiol (CBD) inhibits the growth of human glioma cells both in vitro (e.g., a petri dish) and in animals in a dose-dependent manner. Investigators concluded, “Non-psychoactive CBD produce[s] a significant antitumor activity both in vitro and in vivo, thus suggesting a possible application of CBD as an antineoplastic agent (something which prevents the growth of malignant cells.)”
And finally, a clinical review in the December 2003 issue of the journal Expert Opinion on Therapeutic Targets that summarized “the demonstrated antitumor actions of cannabinoids,” and elaborated on “possible avenues for the future development of cannabinoids as antitumor agents.”
AND SUBSEQUENT MEDIA BLACKOUT
Despite these stunning findings, media coverage of them in North America has been virtually non-existent. As noted by Richard Cowan, editor of the website MarijuanaNews.com, “The New York Times, The Washington Post and Los Angeles Times all ignored this story, even though its newsworthiness is indisputable: a benign substance occurring in nature destroys deadly brain tumors.”
Why the media blackout? For starters, all of these studies were conducted overseas. And secondly, not one of them has been acknowledged by the U.S. government.
U.S. KNEW IN ’74… AND AGAIN IN ’96!